Scarica l'app Stockscreener
0.6998
8.89%
-0.0683
Dopo l'orario di chiusura:
.71
0.0102
+1.46%
Invivyd Inc Borsa (IVVD) Ultime notizie
Adagio Therapeutics stock hits 52-week low at $0.72 By Investing.com - Investing.com UK
Invivyd, Inc. (IVVD) Reports Q3 Loss, Misses Revenue Estimates - MSN
Invivyd (NASDAQ:IVVD) Given New $10.00 Price Target at HC Wainwright - MarketBeat
Invivyd, Inc. (NASDAQ:IVVD) Short Interest Up 15.8% in October - MarketBeat
Invivyd, Inc. (NASDAQ:IVVD) Q3 2024 Earnings Call Transcript - Insider Monkey
Invivyd Inc (IVVD) Quarterly 10-Q Report - Quartzy
Invivyd’s Q3 2024: Revenue Growth and Strategic Developments - TipRanks
IVVD stock touches 52-week low at $0.81 amid market challenges - Investing.com India
Invivyd earnings missed by $0.18, revenue fell short of estimates - Investing.com Canada
Invivyd, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights - The Manila Times
Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor - The Manila Times
Invivyd's PEMGARDA Shows Promise Against COVID Variants Despite Lab Data Dispute | IVVD Stock News - StockTitan
Invivyd Inc (IVVD) Q3 2024 Earnings Report Preview: What to Expect - Yahoo Finance
Invivyd (IVVD) Set to Announce Earnings on Thursday - Defense World
FMR LLC's Strategic Reduction in Invivyd Inc Shares - GuruFocus.com
Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Upload - The Manila Times
Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term - The Bakersfield Californian
Invivyd's COVID Drug Shows 84% Risk Reduction in Phase 3 Trial, Secures FDA Authorization | IVVD Stock News - StockTitan
Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference - The Manila Times
Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference - GlobeNewswire Inc.
Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024 - The Manila Times
Invivyd (IVVD) Sets Q3 2024 Earnings Call: Financial Results & Business Updates Coming Nov 14 | IVVD Stock News - StockTitan
EF Hutton Initiates Coverage of Invivyd (IVVD) with Buy Recommendation - MSN
Invivyd (NASDAQ:IVVD) Upgraded at EF Hutton Acquisition Co. I - Defense World
Invivyd (NASDAQ:IVVD) Upgraded by EF Hutton Acquisition Co. I to "Strong-Buy" Rating - MarketBeat
Invivyd reports preliminary Q3 PEMGARDA product revenue $9.3M - MSN
HC Wainwright Reiterates "Buy" Rating for Invivyd (NASDAQ:IVVD) - MarketBeat
Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA™ (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Part - The Manila Times
Invivyd, Inc. Withdraws Financial Guidance for the Year 2024 - Marketscreener.com
Head to Head Review: Prime Medicine (NYSE:PRME) and Invivyd (NASDAQ:IVVD) - Defense World
Invivyd, Inc. (NASDAQ:IVVD) Short Interest Update - MarketBeat
Guggenheim upgrades Invivyd Inc (IVVD) stock to a Buy - Knox Daily
Invivyd to Present PEMGARDA™ (pemivibart) Data at Infectious Disease Week (IDWeek) 2024 - The Manila Times
Point72 Asia Singapore Pte. Ltd. Sells 40,079 Shares of Invivyd, Inc. (NASDAQ:IVVD) - Defense World
Invivyd Announces U.S. FDA Has Updated the PEMGARDA™ EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity Data - The Manila Times
Invivyd Inc: Rising -81.14% from 52-Week Low, Can the Stock Stay Afloat? - The InvestChronicle
Invivyd Inc [IVVD] Records 200-Day SMA of $2.5044 - Knox Daily
Duquesne Family Office LLC Takes $629,000 Position in Invivyd, Inc. (NASDAQ:IVVD) - MarketBeat
Take off with Invivyd Inc (IVVD): Get ready for trading - SETE News
Invivyd reports stable pemivibart potency against SARS-CoV-2 By Investing.com - Investing.com Canada
Invivyd reports stable pemivibart potency against SARS-CoV-2 - Investing.com
Invivyd Inc (IVVD) is a good investment, but the stock may be undervalued - US Post News
Investor’s Toolkit: Key Ratios for Assessing Invivyd Inc (IVVD)’s Performance - The Dwinnex
Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA™ (pemivibart) - ForexTV.com
Invivyd (IVVD) Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA - StreetInsider.com
Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated - Daily Guardian Canada
Invivyd, Inc.(NasdaqGM: IVVD) dropped from S&P Global BMI Index - Marketscreener.com
Acadian Asset Management LLC Acquires 474,301 Shares of Invivyd, Inc. (NASDAQ:IVVD) - MarketBeat
Biotech Co. Escapes Stock-Drop Suit Over COVID-19 Drug - Law360
Invivyd Inc (IVVD)’s highs and lows: A closer look at its stock price fluctuations - US Post News
0.93%
3.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):